Bennicas & Associates, Inc. Gilead Sciences, Inc. Transaction History
Bennicas & Associates, Inc.
- $157 Million
- Q4 2022
A detailed history of Bennicas & Associates, Inc. transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Bennicas & Associates, Inc. holds 17,166 shares of GILD stock, worth $2.07 Million. This represents 0.94% of its overall portfolio holdings.
Number of Shares
17,166
Previous 17,166
-0.0%
Holding current value
$2.07 Million
Previous $1.47 Million
0.07%
% of portfolio
0.94%
Previous 0.85%
Shares
17 transactions
Others Institutions Holding GILD
# of Institutions
2,338Shares Held
1.03BCall Options Held
12.1MPut Options Held
9.13M-
Black Rock Inc. New York, NY121MShares$14.5 Billion0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA119MShares$14.4 Billion0.22% of portfolio
-
State Street Corp Boston, MA59.2MShares$7.13 Billion0.25% of portfolio
-
Capital World Investors Los Angeles, CA46.3MShares$5.58 Billion0.78% of portfolio
-
Wellington Management Group LLP Boston, MA37.5MShares$4.52 Billion0.79% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $151B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...